Lilly steps up in vaccines with three acquisitions: Deals Report

As Lilly continues to direct some of its massive cash flow toward M&A activity, three of its latest deals are in an area it hadn’t previously prioritized: vaccines.

Eli Lilly and Co. (NYSE:LLY) said Tuesday it will acquire three companies in the vaccine space in agreements whose total value could rise to about $3.8 billion, including milestones. The moves come about seven months after Lilly tapped Peter Marks, a former director of FDA’s Center for Biologics Evaluation and Research (CBER), as its head of infectious disease and SVP of molecule discovery...